Skip to main
OSTX
OSTX logo

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc has demonstrated promising results in its Phase 2b trial for OST-HER2, achieving a two-year overall survival rate of 75% in treated patients, significantly higher than the historical control rate of 40%. The company's upcoming biomarker correlation dataset, expected in November 2025, may strengthen its position for regulatory approval, especially given the supportive indications from major regulatory agencies like the UKMHRA and FDA regarding the use of historical control data. With a solid safety profile and the potential for conditional approval based on overall survival combined with biomarker data, OS Therapies appears well-positioned to advance its innovative treatments for osteosarcoma and other solid tumors.

Bears say

OS Therapies Inc faces significant financial challenges as it operates in a clinical stage environment with no current revenue from product sales, which raises concerns about the sustainability of its operations without additional funding. The company has reported increasing expenses related to research and development, indicating a high burn rate that could dilute shareholder value if further capital is needed to advance its pipeline. Furthermore, the competitive landscape for oncology treatments presents additional risks, as the company may struggle to differentiate its offerings or gain market acceptance amidst established players with more robust financial backing.

OSTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, OSTX has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.